SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer
In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key benefits for patients, the integration of emerging ctDNA targets into treatment decisions has been questioned. Here, we provide further clarification on several aspects of this clinically relevant discussion.
Authors
- Lorenzo Gerratana (ORCID: https://orcid.org/0000-0002-8313-4834)
- Erica L. Mayer (ORCID: https://orcid.org/0000-0001-5430-8957)
- H Iwata
- Nicholas Turner (ORCID: https://orcid.org/0000-0003-0650-4894)
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- E Lim
- L. Sisca
- José Luis Sandoval
- Seth A. Wander
- J Cortés
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- F C Bidard
- A G Giordano
- C X Ma
- J Pascual
- M Ignatiadis
- P A Fasching
- M Cristofanilli
- G Curigliano
- A Brufsky
- Wolfgang Janni
- Stephen Chia
- Yeon Hee Park
- Giampaolo Bianchini
- Kevin Kalinsky
- Joyce O’Shaughnessy
- Carlos Barrios
- Shaheenah Dawood
- Jason A. Mouabbi
- Gustavo Werutsky
- Pedram Razavi
- Arielle J. Medford
Institutions
- University of Geneva (CH)
- BC Cancer Agency (CA)
- University of Udine (IT)
- Université Libre de Bruxelles (BE)
- Royal Marsden NHS Foundation Trust (GB)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Garvan Institute of Medical Research (AU)
- Emory University (US)
- Vita-Salute San Raffaele University (IT)
- Inserm (FR)
- Università Campus Bio-Medico (IT)
- Sarah Cannon Research Institute (GB)
- University of Milan (IT)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Washington University in St. Louis (US)
- Cornell University (US)
- Université Paris-Saclay (FR)
- Texas Oncology (US)
- Institut Jules Bordet (BE)
- Samsung Medical Center (KR)
- Baylor University Medical Center (US)
- Nagoya City University (JP)
- St Vincent's Hospital Sydney (AU)
- Massachusetts General Hospital (US)
- MedSIR (Spain) (ES)
- Magee-Womens Hospital (US)
- Mohammed Bin Rashid University of Medicine and Health Sciences (AE)
- Dana-Farber Cancer Institute (US)
- St Vincent's Clinic (AU)
- Mediclinic City Hospital (AE)
- Centro di Riferimento Oncologico (IT)
- University of Pittsburgh Medical Center (US)
- Campus Bio Medico University Hospital (IT)
- Comprehensive Cancer Center Erlangen (DE)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Canadian Centre for Applied Research in Cancer Control (CA)
- University Hospital Ulm (DE)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Dana-Farber Brigham Cancer Center (US)
- GEICAM – Spanish Breast Cancer Group (ES)
- Weill Cornell Medicine (US)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- European Institute of Oncology (IT)
- Institut Curie (FR)
- Sungkyunkwan University (KR)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-06-08
- DOI
- https://doi.org/10.1038/s41523-026-00967-4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Massachusetts General Hospital
- Università Campus Bio-Medico di Roma